CJC-1295 + Ipamorelin Blend Side Effects and Safety

There is no established human safety profile for a combined CJC-1295 and ipamorelin blend.

Trial readout9 min read

Key takeaway

Published human evidence for CJC-1295 and ipamorelin comes from separate research settings. FDA has identified cardiovascular and other adverse events associated with CJC-1295. An FDA review of ipamorelin describes adverse events in a clinical study, including nausea and blood-pressure changes. These findings do not establish the safety or risks of a combined blend.

At a glance

Article typeTrial readout
Main guideWhere to buy the CJC-1295 + ipamorelin blend
Regulatory statusNot FDA-approved“Neither component is FDA-approved as a drug” (Where to buy the CJC-1295 + ipamorelin blend)
ClassGrowth hormone axis
Body systemsEndocrine & metabolism
Studies cited8 in this article · 22 across 3 articles on CJC-1295 + Ipamorelin blend
ProductCJC-1295 + Ipamorelin blend product page

CJC-1295 ipamorelin side effects are often discussed as if the combination has been tested in clinical trials. The available evidence does not support that assumption. Human findings for each compound separately cannot establish the safety of a combined product.

Quick answer: A reliable human side-effect profile for a CJC-1295 and ipamorelin blend has not been established. Separate evidence includes injection-site and cardiovascular events with CJC-1295, plus nausea and blood-pressure changes in an ipamorelin study. Combination-specific risks remain unknown.

Has a CJC-1295 and ipamorelin blend been studied in humans?

The available sources reviewed for this article do not establish a controlled human trial of a combined CJC-1295 and ipamorelin product.

This is an important evidence gap. A combination can have effects that differ from those of its individual components. Separate studies cannot determine whether adverse events become more frequent or whether new risks emerge when compounds are combined.

A recent orthopaedic review discusses CJC-1295 and ipamorelin together in a mouse model of glucocorticoid-induced muscle loss. That is preclinical evidence, not a human safety trial. Read the review abstract.

What side effects have been reported with CJC-1295?

The available controlled human study of CJC-1295 examined the long-acting DAC form. The study reported no serious adverse reactions. However, FDA's review describes events reported across the available clinical evidence.

These events include injection-site reactions, headache, flushing, diarrhea, nausea, abdominal pain, dizziness and hypotension. FDA also identified serious adverse events involving increased heart rate and systemic vasodilatory reactions.

The data are limited and do not establish the safety of all CJC-1295 forms. Read the FDA briefing.

What side effects have been reported with ipamorelin?

FDA reviewed a clinical study of ipamorelin in patients undergoing bowel surgery. Its briefing describes adverse events in both the ipamorelin and placebo groups.

Three participants in the ipamorelin group discontinued the study drug because of nausea, hypertension or hypotension. The FDA document also discusses serious adverse events, including infections, anastomotic leaks and readmissions.

Two deaths occurred among participants treated with ipamorelin. FDA noted uncertainty about whether those deaths were related to ipamorelin. The clinical setting and postoperative complications make causal interpretation difficult.

These findings should be reported with their study context. They do not prove that ipamorelin caused every event described. Read the FDA briefing document.

What human studies exist for each compound separately?

Four published human studies carry most of this evidence, each on one compound and each small.

Gobburu and colleagues examined ipamorelin in healthy male volunteers using a dose-escalation design. Forty-eight subjects were enrolled, with placebo subjects in every group. FDA’s review notes that the publication did not state that any adverse events occurred. A study that never discusses adverse events has not shown their absence. Read the volunteer study record.

Beck and colleagues reported the only published clinical trial in patients. It was a phase 2, randomized, double-blind, placebo-controlled study in adults having bowel resection, with 117 patients enrolled and 114 in the safety population. Treatment-emergent adverse events were reported in 87.5% of the ipamorelin group and 94.8% of the placebo group. FDA’s review lists hypokalemia at 12.5% versus 3.4%, insomnia at 10.7% versus 5.2%, and hyperglycemia at discharge at 14.3% versus 8.6%. Read the trial record.

Raun and colleagues first described ipamorelin’s selectivity, using rat pituitary cells, anesthetized rats and conscious swine. In swine, the peptide did not change FSH, LH, prolactin or TSH levels. It also did not raise ACTH or cortisol, as two comparison peptides did. That is cell and animal evidence, not a human safety result. Read the selectivity paper.

On the CJC-1295 side, Teichman and colleagues ran two randomized, placebo-controlled, ascending-dose trials. Both enrolled healthy adults aged 21 to 61, and ran 28 and 49 days. Ionescu and Frohman later measured growth hormone pulsatility overnight in 12 healthy men. FDA’s review records no serious adverse events in that second study, alongside a heart rate increase and transient injection-site redness and tenderness. Read the CJC-1295 trial report and the pulsatility study.

Across the published CJC-1295 studies, FDA counted 63 healthy adults. Men made up 87%, and 73% had only one exposure.

Table 1

What each evidence source can and cannot show

Evidence sourceCompoundPopulation and sizeReported adverse eventsWhat it cannot tell us about a blend
Gobburu et al., 1999Ipamorelin48 healthy male volunteers; dose-escalation pharmacology studyNone stated in the publication, per FDA’s reviewShort exposure in healthy men; no CJC-1295 group
Beck et al., 2014Ipamorelin117 adults enrolled after bowel resection; phase 2, placebo-controlledHypokalemia, insomnia and hyperglycemia above placebo; serious events in both groups; two deaths among treated patientsSurgical illness clouds attribution; no participant received CJC-1295
Raun et al., 1998IpamorelinRat pituitary cells, anesthetized rats and conscious swineNo change in FSH, LH, prolactin or TSH; no significant ACTH or cortisol riseCell and animal work; no human event rates
Teichman et al., 2006CJC-1295 DACHealthy adults; two randomized, placebo-controlled trials, 28 and 49 daysInjection-site reactions, headache, diarrhea, flushing and transient hypotension, per FDA’s reviewHealthy volunteers only, short duration, no ipamorelin group
Ionescu and Frohman, 2006CJC-1295 DAC12 healthy men studied overnightNo serious events; heart rate increase; injection-site redness and tendernessOne session; nothing about repeated or combined exposure

Could combining the compounds change the risk profile?

It is not known. Combining two compounds that influence the growth hormone pathway does not mean their effects or risks can be predicted by adding separate trial results.

Potential interactions, combined hormone effects and formulation-related risks have not been adequately characterized in human studies of the blend. There is also no established clinical evidence that a blend has the same composition or exposure characteristics across products.

A responsible evidence summary should therefore distinguish documented events from unanswered questions. Combination-specific adverse events are not established.

Why is there no direct evidence for the combination?

No one has registered the study that would answer the question. A ClinicalTrials.gov search on November 18, 2026 for trials listing both compounds as interventions returned no records.

The registered studies cover each compound alone. Ipamorelin has two completed phase 2 trials: a study in 117 adults and a larger dose-finding study in 320 patients. Results were never posted for the second. CJC-1295 appears in one phase 2 study in people with HIV-associated visceral obesity, which is listed as terminated.

Mechanism is the second reason. FDA’s review describes CJC-1295 as an analogue of growth hormone releasing hormone that acts at GHRH receptors on pituitary somatotroph cells. Ipamorelin instead acts at the ghrelin receptor, GHS-R1a, a receptor first cloned and described in 1996. See how ipamorelin acts at GHS-R for that pathway in detail.

Two receptors mean combined effects cannot be inferred by addition. Earlier work in 18 healthy men found that a growth hormone releasing peptide and GHRH together raised growth hormone synergistically. Those were different compounds, so the result does not describe this blend. It does show that the two pathways can interact, which is a reason to measure a combination rather than assume it. Read the 1990 report.

Adverse event reporting carries the same problem. FDA reviewed a report on a compounded product that held ipamorelin and a second peptide. The agency wrote that it could not assess a relationship between ipamorelin specifically and the event.

What does FDA say about the safety of these compounds?

FDA has identified CJC-1295-related concerns involving immunogenicity, peptide impurities and characterization. It has also identified serious adverse events involving increased heart rate and systemic vasodilatory reactions.

FDA's ipamorelin briefing discusses clinical safety data from a surgical population. It notes adverse events and deaths in treated participants, while acknowledging uncertainty about causation.

FDA review documents assess safety concerns. They do not constitute approval of either compound or a combined product.

How do regulators classify these two compounds?

FDA publishes a list of bulk drug substances that may present significant safety risks, called category 2 under its interim compounding policies. Both compounds appear there, on a page current as of April 22, 2026.

The CJC-1295 entry cites immunogenicity risk for certain routes, plus complexity around peptide-related impurities and ingredient characterization. It also cites serious adverse events, including increased heart rate and systemic vasodilatory reaction, and limited clinical data. Read the FDA category 2 list.

The ipamorelin acetate entry cites the same immunogenicity and characterization concerns. It notes that the peptide contains unnatural amino acids. It also refers to serious adverse events including death in the published hospital study. FDA added it to category 2 on September 29, 2023.

Both 2024 review memos reached the same proposal. Each recommended against adding the substance to the section 503A bulk drug substances list. For CJC-1295, FDA cited characterization gaps, an unclear history in compounding, nonclinical safety signals and missing clinical data. The advisory committee meeting held on July 23 and 24, 2026 reviewed a different set of peptides and did not revisit either compound.

The WADA 2026 Prohibited List took force on January 1, 2026. It names CJC-1295 among GHRH analogues and ipamorelin among growth hormone secretagogues, both in section S2.2.4. Both are prohibited at all times, in and out of competition. Read the 2026 list. Neither classification establishes a human safety profile for a blend.

Why is the evidence for blends especially limited?

A blend introduces additional questions about identity, composition, stability and consistency. Without a well-characterized product and controlled human study, researchers cannot reliably attribute an event to one ingredient or the combination.

The evidence also depends on the exact CJC-1295 form. DAC and non-DAC substances are not interchangeable evidence categories.

For these reasons, a side-effect list for the individual compounds should not be presented as a proven side-effect list for the blend.

For more background, see Vitrapep’s CJC-1295 side effects, ipamorelin side effects, CJC-1295 vs ipamorelin comparison and CJC-1295 complete guide. For why there is no approved dose, see why research peptides have no dose.

Vitrapep research material

Vitrapep sells CJC-1295 / ipamorelin blend for laboratory research use only. It is not for human or veterinary use.

CJC-1295 / Ipamorelin Blend 10 mg research vial

CJC-1295 / Ipamorelin Blend

Lyophilized Research use only

Specifications for the CJC-1295 / ipamorelin blend sold for laboratory research. COA available with each lot.

View CJC-1295 / ipamorelin blend specifications

Frequently asked questions

Are CJC-1295 and ipamorelin proven safe together?

No. The available sources do not establish a controlled human safety profile for the combination.

What are the known CJC-1295 side effects?

FDA materials describe injection-site reactions, headache, flushing, gastrointestinal symptoms, dizziness, hypotension and increased heart rate.

What are the known ipamorelin side effects?

An FDA-reviewed surgical study reported nausea and blood-pressure changes among reasons for discontinuation. The FDA document also describes serious postoperative events and notes uncertainty about causation.

Have deaths been reported in an ipamorelin study?

Yes. FDA's review describes two deaths among ipamorelin-treated participants in a surgical study. It states that the relationship between treatment and those deaths is unclear.

Does animal research prove the blend works or is safe in people?

No. Animal findings can inform research questions. They cannot establish human efficacy or safety.

Is there a registered trial of the two compounds together?

No. A ClinicalTrials.gov search on November 18, 2026 for studies listing both compounds returned no records.

Do CJC-1295 and ipamorelin act on the same receptor?

No. FDA reviews describe CJC-1295 as a GHRH analogue acting at GHRH receptors, while ipamorelin acts at the ghrelin receptor GHS-R1a.

Are both compounds prohibited in sport?

Yes. The WADA 2026 Prohibited List names both in section S2.2.4, which is prohibited at all times. That classification concerns sport, not laboratory safety.

What to know now

  • Combination-specific human safety data for CJC-1295 plus ipamorelin are not established.
  • Separate FDA reviews describe adverse events for each compound, but in different research contexts.
  • Animal combination findings do not establish human safety or effectiveness.

What we’re watching

  • Any registered, controlled human trial that evaluates the actual combination.
  • New FDA safety reviews for CJC-1295 and ipamorelin.
  • Research that identifies the exact CJC-1295 form and blend composition.
  • Whether a future FDA advisory committee briefing revisits either substance.

Also in the library

More for endocrine & metabolism

All 41 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration 2024, FDA briefing document: CJC-1295-related bulk drug substances; U.S. Food and Drug Administration 2024, October 29, 2024 Pharmacy Compounding Advisory Committee briefing document; Tham 2026, PubMed record; Gobburu 1999, Pharmaceutical Research, 16; Beck 2014, International Journal of Colorectal Disease, 29; Raun 1998, European Journal of Endocrinology, 139; Teichman 2006, Journal of Clinical Endocrinology & Metabolism, 91; Ionescu 2006, Journal of Clinical Endocrinology & Metabolism, 91; Howard 1996, Science, 273; Bowers 1990, Journal of Clinical Endocrinology & Metabolism, 70; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2025, The 2026 prohibited list: World Anti-Doping Code international standard. All 12 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2024). FDA briefing document: CJC-1295-related bulk drug substances. https://www.fda.gov/media/183819/download
  2. U.S. Food and Drug Administration. (2024). October 29, 2024 Pharmacy Compounding Advisory Committee briefing document. https://www.fda.gov/media/182088/download?attachment=
  3. Tham, A., Hodgkins, C. W., & Kennedy, J. G. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. PubMed record. https://pubmed.ncbi.nlm.nih.gov/41476424/
  4. Gobburu, J. V. S., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/
  5. Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534. https://pubmed.ncbi.nlm.nih.gov/25331030/
  6. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/
  7. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
  8. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
  9. Howard, A. D., Feighner, S. D., Cully, D. F., et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974-977. https://pubmed.ncbi.nlm.nih.gov/8688086/
  10. Bowers, C. Y., Reynolds, G. A., Durham, D., Barrera, C. M., Pezzoli, S. S., & Thorner, M. O. (1990). Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 70(4), 975-982. https://pubmed.ncbi.nlm.nih.gov/2108187/
  11. U.S. Food and Drug Administration. (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  12. World Anti-Doping Agency. (2025). The 2026 prohibited list: World Anti-Doping Code international standard. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf